Steinar Aamdal
Papers
1
Total Citations
30
H-Index
1
About
Steinar Aamdal is a pioneering figure in cancer immunotherapy, with a career-long focus on developing personalized dendritic cell (DC) vaccines for high-risk malignancies. His seminal work includes the landmark long-term Phase I/II study of an adjuvant DC vaccine for patients with high-risk prostate cancer following radical prostatectomy. This first-in-man trial demonstrated the vaccine's safety and potential to reduce biochemical relapse, offering a new avenue for preventing disease recurrence in a population with limited curative options. With over 30 citations, this study underscores his contribution to translating complex immunology into tangible clinical benefit. Aamdal’s research bridges the gap between bench and bedside, emphasizing patient-specific immune activation. His achievements include advancing vaccine strategies for solid tumors and shaping early-phase trial design for personalized oncology. For students and researchers, Aamdal’s work exemplifies how targeted immunotherapy can transform post-surgical cancer management, highlighting the promise of dendritic cell vaccines in high-risk settings.
Research Focus
Key Achievements
Top Papers
- 1